Mood and Psychotic Disorders Biodesign workshop

Event Information

Share this event

Date and Time





United Kingdom

View Map

Event description


This event is co-hosted by MindTech (NIHR Mental Health MedTech Co-operative) and the University of Nottingham.

According to the charity Mind, approximately 1 in 4 people in the UK experience a mental health problem each year. Many do not seek help and even when referred to psychological services within the NHS only 40% receive therapy. This means around 3 in 4 people with a mental illness are currently not receiving any treatment.

Mood disorders are comprised of a range of mental illnesses which include depression, anxiety disorders and bipolar disorder. They can affect people of all ages; 10% of British 5-15 year olds have a diagnosable mental health condition but only 25% of these receive support. More than 75% of adults who access mental health services had a diagnosable disorder prior to the age of 18. Psychotic disorders such as schizophrenia are also often experienced alongside mood disorders. Self-harm, suicidal feelings and other symptoms of mental illness are closely related to both mood and psychotic disorders.

Mood disorders are often treated with antidepressant and mood stabilising medicines; however, these can cause a wide range of unpleasant side effects. There are a range of non-pharmaceutical treatments currently being investigated and some are already available for patients. Neuromodulation techniques such as transcranial magnetic stimulation (TMS) are in use and are being evaluated in the NHS. There have been some promising results for deep brain stimulation and vagus nerve stimulation in the treatment of depression. Recently there have also been some very exciting studies which have shown that virtual reality has the potential to deliver rapid, lasting improvements in mental health.

This workshop is being run in collaboration with MindTech. It will take a biodesign approach and aims to bring together clinicians, companies, academics, charities and other stakeholders, to accelerate the development of new neurotechnologies to treat mood and psychotic disorders.


09:30 Registration and coffee

10:00 Welcome and introduction to the SIG - Dr Charlie Winkworth-Smith, KTN

10:10 Introduction to Mindtech - Dr Michael Craven, University of Nottingham

10:20 Overview of mood and psychotic disorders and the TMS Magstim depression trial - Prof Richard Morriss

10:50 A patient's voice from the Lived Experience Advisory Panel - Tom Willis, Lived Experience Advisory Panel

11:10 Introduction to NICE - Dr Chris Pomfrett, NICE

11:30 Refreshments and Demo space

12:00 Brain Computer Interfaces for depression - Dr Mahnaz Arvaneh, University of Sheffield

12:20 gamechanger Virtual reality - Dr Sinead Lambe, University of Oxford

12:40 The Entrepreneurial Perspective - Steve Hutchinson, The Microcurrent Site Ltd. (Alpha-Stim)

13:00 Lunch and Demo space

14:00 Biodesign needs summary - table themes

15:00 Table report outs - summary of needs

15:30. Discussion

15:50 Closing remarks

16:00 Refreshments and Demo space

How will registration work?

We will operate an Expression of Interest scheme and endeavour to confirm your space at the event as soon as possible. Selection of delegates is on the basis of alignment with the topics covered by the event, experience, type of organisation and geography. We reserve the right to limit participation to one representative per organisation if required.

PLEASE NOTE: there will be a small demo space, if you are interested in demonstrating a technology, please email

For any queries please contact:

Charlie Winkworth-Smith, Knowledge Transfer Manager Emerging Technologies

Poonam Phull, Events Manager

Date and Time




United Kingdom

View Map

Save This Event

Event Saved